Market revenue in 2023 | USD 41.3 million |
Market revenue in 2030 | USD 341.8 million |
Growth rate | 35.2% (CAGR from 2023 to 2030) |
Largest segment | Autologous therapies |
Fastest growing segment | Autologous Therapies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Allogeneic Therapies, Autologous Therapies |
Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy market will help companies and investors design strategic landscapes.
Autologous therapies was the largest segment with a revenue share of 99.27% in 2023. Horizon Databook has segmented the Switzerland cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The cell therapy market in Switzerland is expected to witness growth due to the presence of key players and increasing expansion activities undertaken by them. Switzerland is known as the home country of major pharmaceutical & biotechnology companies like Roche, Novartis, and numerous other leading companies.
The companies operating in the country are focusing on increasing their presence in cell and gene therapy. Several companies are undertaking expansion activities to increase access to cell and gene therapy in the Switzerland market. For instance, in November 2019, Novartis opened its gene and cell therapy facility in Switzerland to manufacture various cell therapies.
Furthermore, in May 2022, Cytiva introduced its new manufacturing facility in Grens, Switzerland, which served as the base of processes for its cell and gene therapy-related operations. Such expansions of manufacturing capacities for cell and gene therapies are expected to drive the market competition in Switzerland.
Horizon Databook provides a detailed overview of country-level data and insights on the Switzerland cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into Switzerland cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account